News & Updates

In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Tetracycline demonstrates superior clinical efficacy to that of macrolide in children with macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia, a study has shown.

Treatment with ivermectin for mild-to-moderate COVID-19 does not appear to reduce recovery time as compared with placebo, according to data from the ongoing ACTIV-6* study.

Treatment with high-dose sulbactam leads to higher mid-dosing (Cmid) and pharmacokinetic-pharmacodynamic (PK-PD) achievement in paediatric patients, reports a study.

People with post-vaccination syndrome (PVS), a rare condition following receipt of COVID-19 jabs, exhibit distinct immunological patterns, including the reappearance of the dormant Epstein-Barr virus (EBV) and persistence of SARS-CoV-2 spike protein in the blood, according to new research.

Infection with the human papillomavirus (HPV) contributes to an increased risk of developing hidradenitis suppurativa (HS), indicating a potential association, reveals a study.

Implementation of or compliance with the Severe Sepsis and Septic Shock Management Bundle (SEP-1) does not appear to contribute to mortality among patients with sepsis, as shown by the results of a systematic review.